

SPARK EUROPE WEBINAR SERIES 2022-2023

Wednesdays
at 16.00 CET



A view from the Bridge; Drug development from the perspective of a Venture Capital fund bridging the gap between Academic research and Industry

Dr. Ariel Kamsler

Wednesday, January 11th, 2023 at 4-5 pm (CET) | Online Webinar

- What is the road a therapeutic travels from the lab to the clinic? What is the cost? How is it funded? How is value created for patients, for investors and for inventors?
- What does a VC fund contribute to the process? Why should an inventor meet them? When should an inventor meet them?
- What are some ways in which an academic lab can better prepare a project for industry attention and funding?

Ariel Kamsler, Ph.D.

Associate and Head of Search and Evaluation at Israel Biotech Fund. Ariel has years of experience in drug development management and evaluation.

Ariel's BSc and MSc studies were carried out in Tel Aviv University studying Biology and Neurobiochemistry. Ariel holds a Ph.D. in Neurobiology from the Weizmann Institute and his postdoctoral training was carried out at MIT.

Ariel worked at Teva, where he was a formulation researcher and project manager responsible for new product evaluations. Ariel led the formulation lab at CTS pharmaceutical industries and was later responsible for clinical operations at RDD Pharma.

Israel Biotech Fund is a VC fund focused on drug development companies based in Israel, the fund invests directly in companies in all stages of development and is active in company formation using pharmaceutical assets licensed from Pharma and from Academia.



Online via Zoom – Please register [here!](#)

Registration for the webinar is required in advance. Please register no later than 10 January.

SPARK TEL AVIV | WEB: <http://spark-telaviv.tau.ac.il> | TEL: 972-03-6407241 | Mail: sparktau@tauex.tau.ac.il

